T cell leukemia
METHODS: The in vitro activity of BSK805, a new JAK II inhibitor (Novartis Pharmaceuticals), was analyzed in 10 hematopoietic cell lines, including 5 BCR-ABL positive (K-562, KCL-22, KU812, Lama-87, BV173), 4 JAK II V617F positive (CHRF-288, SET-2, UKE-1, HEL) and the T cell leukemia line Jurkat.